| Literature DB >> 31627339 |
Catarina Garcia1,2, Epole Ntungwe3,4, Ana Rebelo5,6, Cláudia Bessa7, Tijana Stankovic8, Jelena Dinic9, Ana Díaz-Lanza10, Catarina P Reis11, Amílcar Roberto12, Paula Pereira13,14, Maria-João Cebola15,16, Lucília Saraiva17, Milica Pesic18, Noélia Duarte19, Patrícia Rijo20,21.
Abstract
The Plectranthus genus is commonly used in traditional medicine due to its potential to treat several illnesses, including bacterial infections and cancer. As such, aiming to screen the antibacterial and cytotoxic activities of extracts, sixteen selected Plectranthus species with medicinal potential were studied. In total, 31 extracts obtained from 16 Plectranthus spp. were tested for their antibacterial and anticancer properties. Well diffusion method was used for preliminary antibacterial screening. The minimum inhibitory concentration (MIC) and minimal bactericidal concentration (MBC) values of the five most active acetonic extracts (P. aliciae, P. japonicus, P. madagascariensis var. "Lynne", P. stylesii, and P. strigosus) were determined. After preliminary toxicity evaluation on Artemia salina L., their cytotoxic properties were assessed on three human cancer cell lines (HCT116, MCF-7, and H460). These were also selected for mechanism of resistance studies (on NCI-H460/R and DLD1-TxR cells). An identified compound-parvifloron D-was tested in a pair of sensitive and MDR-Multidrug resistance cancer cells (NCI-H460 and NCI-H460/R) and in normal bronchial fibroblasts MRC-5. The chemical composition of the most active extract was studied through high performance liquid chromatography with a diode array detector (HPLC-DAD/UV) and liquid chromatography-mass spectrometry (LC-MS). Overall, P. strigosus acetonic extract showed the strongest antimicrobial and cytotoxic potential that could be explained by the presence of parvifloron D, a highly cytotoxic diterpene. This study provides valuable information on the use of the Plectranthus genus as a source of bioactive compounds, namely P. strigosus with the potential active ingredient the parvifloron D.Entities:
Keywords: P. strigosus; Plectranthus; antimicrobial; cytotoxicity; parvifloron D
Year: 2019 PMID: 31627339 PMCID: PMC6843537 DOI: 10.3390/biom9100616
Source DB: PubMed Journal: Biomolecules ISSN: 2218-273X
Minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) values of Plectranthus spp. acetonic extracts against tested bacteria (results expressed in μg/mL).
| Acetonic Extracts | Gram-Positive Bacteria | |||
|---|---|---|---|---|
| MIC | MBC | MIC | MBC | |
|
| 15.6 | 125 | 62.5 | 125 |
|
| 62.5 | 125 | 62.5 | 125 |
| 15.6 | >125 | 125 | 125 | |
|
| 15.6 | >62.5 | 125 | 125 |
|
| 31.3 | >125 | 62.5 | 250 |
| Positive control (VAN) | 1.95 | 7.82 | ||
| Negative control (DMSO) | >500 | >500 | ||
VAN—vancomycin (1 mg/mL); NOR—norfloxacin (1 mg/mL).
A. salina general toxicity results LC50 (μg/mL) of acetonic extracts of the selected Plectranthus spp.
| Acetonic Extracts | Mortality Rate (%) at 100 ppm Concentration | LC50 (μg/mL) |
|---|---|---|
|
| 16.71 ± 1.01 | 53.48 |
|
| 21.85 ± 0.35 | 38.9 |
| 9.67 ± 0.93 | 91.7 | |
|
| 16.30 ± 0.99 | 110.76 |
|
| 42.88 ± 2. 21 | 13.62 |
| DMSO | 22.50 ± 3.54 | N.A. |
N.A.—non applicable.
Figure 1Growth inhibition of 50% (GI50) values (μg/mL) of Plectranthus spp. extracts in HCT116 (a), MCF-7 (b), and NCI-H460 (c) cells were determined after 48 h treatment using the SRB assay. Data are mean ± SEM (n = 3,4). Doxorubicin was used as a positive control (GI50: 54.00 ± 3.24 ng/mL in HCT116, 85.17 ± 4.10 ng/mL in MCF-7, 292.01 ± 2.32 ng/mL in NCI-H460 cells).
Figure 2Sensitivity of MDR (MultiDrug Resistance) cancer cells and their corresponding sensitive cells to acetonic Plectranthus extracts. The IC50 (half maximal inhibitory concentration) was determined using SRB assay after 72 h treatment with acetonic extracts. Statistical analysis was performed in GraphPad Prism 6 by two-way ANOVA: *** indicates the resistance to the specific extract (p < 0.001); ### indicates the collateral sensitivity to the specific extract (p < 0.001).
Figure 3Anticancer effects of parvifloron D. The cytotoxicity was assessed by MTT—3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide—assay after 72 h treatment in NCI-H460, NCI-H460/R, and MRC-5 cells (A). Rho 123 accumulation was evaluated as an indicator of P-glycoprotein (P-gp) function in NCI-H460/R cells untreated and treated with parvifloron D (B).